Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 5/2021

28.04.2021 | Research Article

Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life

verfasst von: Tatjana Van Der Heggen, Franky M. Buyle, Barbara Claus, Annemie Somers, Petra Schelstraete, Peter De Paepe, Sophie Vanhaesebrouck, Pieter A. J. G. De Cock

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Background Correct dosing and therapeutic drug monitoring (TDM) practices are essential when aiming for optimal vancomycin treatment. Objective To assess target attainment after initial dosing and dose adjustments, and to determine compliance to dosing and TDM guidelines. Setting Tertiary care university hospital in Belgium. Method A chart review was performed in 150 patients, ranging from preterm infants to adults, treated intravenously with vancomycin. Patient characteristics, dosing and TDM data were compared to evidence-based hospital guidelines. Main outcome measures Target attainment of vancomycin after initial dosing and dose adjustments. Results Subtherapeutic concentrations were measured in 68% of adults, in 76% of children and in 52% of neonates after treatment initiation. Multiple dose adaptations (median 2, Q1 1–Q3 2) were required for target attainment, whilst more than 20% of children and neonates never reached targeted concentrations. Regarding compliance to the hospital guideline, some points of improvement were identified: omitted dose adjustment in adults with decreased renal function (53%), delayed sampling (16% in adults, 31% in children) and redundant sampling (34% of all samples in adults, 12% in children, 13% in neonates). Conclusion Target attainment for vancomycin with current dosing regimens and TDM is poor in all age groups. Besides, human factors should not be ignored when aiming for optimal treatment. This study reflects an ongoing challenge in clinical practice and highlights the need for optimization of vancomycin dosing strategies and improvement of awareness of all health care professionals involved.
Literatur
2.
Zurück zum Zitat Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus Aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020;71(6):1361–4.PubMedCrossRef Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus Aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020;71(6):1361–4.PubMedCrossRef
3.
Zurück zum Zitat McNeil JC, Kaplan SL. Vancomycin therapeutic drug monitoring in children: new recommendations, similar challenges. J Pediatr Pharmacol Ther. 2020;25(6):472–5.PubMedPubMedCentral McNeil JC, Kaplan SL. Vancomycin therapeutic drug monitoring in children: new recommendations, similar challenges. J Pediatr Pharmacol Ther. 2020;25(6):472–5.PubMedPubMedCentral
4.
Zurück zum Zitat Pham JT. Challenges of vancomycin dosing and therapeutic monitoring in neonates. J Pediatr Pharmacol Ther. 2020;25(6):476–84.PubMedPubMedCentral Pham JT. Challenges of vancomycin dosing and therapeutic monitoring in neonates. J Pediatr Pharmacol Ther. 2020;25(6):476–84.PubMedPubMedCentral
5.
Zurück zum Zitat Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M, et al. Therapeutic monitoring of vancomycin in adults: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82–98.PubMedCrossRef Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M, et al. Therapeutic monitoring of vancomycin in adults: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82–98.PubMedCrossRef
6.
Zurück zum Zitat Men P, Li HB, Zhai SD, Zhao RS. Association between the AUC0-24/MIC ratio of vancomycin and its clinical effectiveness: a systematic review and meta-analysis. PLoS ONE. 2016;11(1):e0146224.PubMedPubMedCentralCrossRef Men P, Li HB, Zhai SD, Zhao RS. Association between the AUC0-24/MIC ratio of vancomycin and its clinical effectiveness: a systematic review and meta-analysis. PLoS ONE. 2016;11(1):e0146224.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(Suppl 1):S35–9.PubMedCrossRef Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(Suppl 1):S35–9.PubMedCrossRef
8.
Zurück zum Zitat Buyle FM, Decruyenaere J, De Waele J, Tulkens PM, Van Audenrode T, Depuydt P, et al. A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals. Eur J Clin Microbiol Infect Dis. 2013;32:763–8.PubMedCrossRef Buyle FM, Decruyenaere J, De Waele J, Tulkens PM, Van Audenrode T, Depuydt P, et al. A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals. Eur J Clin Microbiol Infect Dis. 2013;32:763–8.PubMedCrossRef
9.
Zurück zum Zitat Suchartlikitwong P, Anugulruengkitt S, Wacharachaisurapol N, Jantarabenjakul W, Sophonphan J, Theerawit T, et al. Optimizing vancomycin use through 2-point AUC-based therapeutic drug monitoring in pediatric patients. J Clin Pharmacol. 2019;59(12):1597–605.PubMedCrossRef Suchartlikitwong P, Anugulruengkitt S, Wacharachaisurapol N, Jantarabenjakul W, Sophonphan J, Theerawit T, et al. Optimizing vancomycin use through 2-point AUC-based therapeutic drug monitoring in pediatric patients. J Clin Pharmacol. 2019;59(12):1597–605.PubMedCrossRef
10.
Zurück zum Zitat Janssen EJ, Valitalo PA, Allegaert K, de Cock RF, Simons SH, Sherwin CM, et al. Towards rational dosing algorithms for vancomycin in neonates and infants based on population pharmacokinetic modeling. Antimicrob Agents Chemother. 2016;60:1013–21.PubMedPubMedCentralCrossRef Janssen EJ, Valitalo PA, Allegaert K, de Cock RF, Simons SH, Sherwin CM, et al. Towards rational dosing algorithms for vancomycin in neonates and infants based on population pharmacokinetic modeling. Antimicrob Agents Chemother. 2016;60:1013–21.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Fiorito TM, Luther MK, Dennehy PH, LaPlante KL, Matson KL. Nephrotoxicity with vancomycin in the pediatric population: a systematic review and meta-analysis. Pediatr Infect Dis J. 2018;37:654–61.PubMedCrossRef Fiorito TM, Luther MK, Dennehy PH, LaPlante KL, Matson KL. Nephrotoxicity with vancomycin in the pediatric population: a systematic review and meta-analysis. Pediatr Infect Dis J. 2018;37:654–61.PubMedCrossRef
12.
Zurück zum Zitat Le J, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32:e155–63.PubMedPubMedCentralCrossRef Le J, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32:e155–63.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Waineo MF, Kuhn TC, Brown DL. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion. J Clin Pharm Ther. 2015;40:259–65.PubMedCrossRef Waineo MF, Kuhn TC, Brown DL. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion. J Clin Pharm Ther. 2015;40:259–65.PubMedCrossRef
14.
Zurück zum Zitat Saugel B, Gramm C, Wagner JY, Messer M, Lahmer T, Meidert AS, et al. Evaluation of a dosing regimen for continuous vancomycin infusion in critically ill patients: an observational study in intensive care unit patients. J Crit Care. 2014;29:351–5.PubMedCrossRef Saugel B, Gramm C, Wagner JY, Messer M, Lahmer T, Meidert AS, et al. Evaluation of a dosing regimen for continuous vancomycin infusion in critically ill patients: an observational study in intensive care unit patients. J Crit Care. 2014;29:351–5.PubMedCrossRef
15.
Zurück zum Zitat Vuagnat A, Stern R, Lotthe A, Schuhmacher H, Duong M, Hoffmeyer P, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther. 2004;29:351–7.PubMedCrossRef Vuagnat A, Stern R, Lotthe A, Schuhmacher H, Duong M, Hoffmeyer P, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther. 2004;29:351–7.PubMedCrossRef
16.
Zurück zum Zitat Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285–92.PubMedCrossRef Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285–92.PubMedCrossRef
17.
Zurück zum Zitat Dersch-Mills D, Bengry T, Akierman A, Alshaikh B, Yusuf K. Assessment of initial vancomycin dosing in neonates. Paediatr Child Health. 2014;19:e30–4.PubMedPubMedCentralCrossRef Dersch-Mills D, Bengry T, Akierman A, Alshaikh B, Yusuf K. Assessment of initial vancomycin dosing in neonates. Paediatr Child Health. 2014;19:e30–4.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Ye ZK, Chen YL, Chen K, Zhang XL, Du GH, He B, et al. Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society. J Antimicrob Chemother. 2016;71:3020–5.PubMedCrossRef Ye ZK, Chen YL, Chen K, Zhang XL, Du GH, He B, et al. Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society. J Antimicrob Chemother. 2016;71:3020–5.PubMedCrossRef
19.
Zurück zum Zitat Sosnin N, Curtis N, Cranswick N, Chiletti R, Gwee A. Vancomycin is commonly under-dosed in critically ill children and neonates. Br J Clin Pharmacol. 2019;85:2591–8.PubMedPubMedCentralCrossRef Sosnin N, Curtis N, Cranswick N, Chiletti R, Gwee A. Vancomycin is commonly under-dosed in critically ill children and neonates. Br J Clin Pharmacol. 2019;85:2591–8.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Mehrotra N, Tang L, Phelps SJ, Meibohm B. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations. Pharmacotherapy. 2012;32:408–19.PubMedCrossRef Mehrotra N, Tang L, Phelps SJ, Meibohm B. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations. Pharmacotherapy. 2012;32:408–19.PubMedCrossRef
21.
Zurück zum Zitat Obara VY, Zacas CP, Carrilho CM, Delfino VD. Currently used dosage regimens of vancomycin fail to achieve therapeutic levels in approximately 40% of intensive care unit patients. Rev Bras Ter Intensiva. 2016;28:380–6.PubMedPubMedCentralCrossRef Obara VY, Zacas CP, Carrilho CM, Delfino VD. Currently used dosage regimens of vancomycin fail to achieve therapeutic levels in approximately 40% of intensive care unit patients. Rev Bras Ter Intensiva. 2016;28:380–6.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Bakke V, Sporsem H, Von der Lippe E, Nordoy I, Lao Y, Nyrerod HC, et al. Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study. Acta Anaesthesiol Scand. 2017;61:627–35.PubMedPubMedCentralCrossRef Bakke V, Sporsem H, Von der Lippe E, Nordoy I, Lao Y, Nyrerod HC, et al. Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study. Acta Anaesthesiol Scand. 2017;61:627–35.PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Ringenberg T, Robinson C, Meyers R, Degnan L, Shah P, Siu A, Sturgill M. Achievement of therapeutic vancomycin trough serum concentrations with empiric dosing in neonatal intensive care unit patients. Pediatr Infect Dis J. 2015;34:742–7.PubMedCrossRef Ringenberg T, Robinson C, Meyers R, Degnan L, Shah P, Siu A, Sturgill M. Achievement of therapeutic vancomycin trough serum concentrations with empiric dosing in neonatal intensive care unit patients. Pediatr Infect Dis J. 2015;34:742–7.PubMedCrossRef
24.
Zurück zum Zitat Patel J, Lucas CJ, Ryan J, Jenkins M, Martin JH. Vancomycin therapeutic drug monitoring in paediatrics. J Paediatr Child Health. 2020;56:563–70.PubMedCrossRef Patel J, Lucas CJ, Ryan J, Jenkins M, Martin JH. Vancomycin therapeutic drug monitoring in paediatrics. J Paediatr Child Health. 2020;56:563–70.PubMedCrossRef
25.
Zurück zum Zitat Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.PubMedPubMedCentralCrossRef Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4:1832–43.PubMedCrossRef Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4:1832–43.PubMedCrossRef
27.
Zurück zum Zitat Brion LP, Fleischman AR, McCarton C, Schwartz GJ. A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: noninvasive assessment of body composition and growth. J Pediatr. 1986;109:698–707.PubMedCrossRef Brion LP, Fleischman AR, McCarton C, Schwartz GJ. A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: noninvasive assessment of body composition and growth. J Pediatr. 1986;109:698–707.PubMedCrossRef
28.
Zurück zum Zitat Muhari-Stark E, Burckart GJ. Glomerular filtration rate estimation formulas for pediatric and neonatal use. J Pediatr Pharmacol Ther. 2018;23:424–31.PubMedPubMedCentral Muhari-Stark E, Burckart GJ. Glomerular filtration rate estimation formulas for pediatric and neonatal use. J Pediatr Pharmacol Ther. 2018;23:424–31.PubMedPubMedCentral
29.
Zurück zum Zitat Belgian Society of Infectious Diseases and Clinical Microbiology. Osteomyelitis, spondylodiscitis: acute infection caused by methicillin resistant staphylococcus. https://www.bvikm.org. Accessed 4 January 2021. Belgian Society of Infectious Diseases and Clinical Microbiology. Osteomyelitis, spondylodiscitis: acute infection caused by methicillin resistant staphylococcus. https://​www.​bvikm.​org. Accessed 4 January 2021.
30.
Zurück zum Zitat de Hoog M, Mouton JW, van den Anker JN. Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet. 2004;43:417–40.PubMedCrossRef de Hoog M, Mouton JW, van den Anker JN. Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet. 2004;43:417–40.PubMedCrossRef
31.
Zurück zum Zitat Madigan T, Sieve RM, Graner KK, Banerjee R. The effect of age and weight on vancomycin serum trough concentrations in pediatric patients. Pharmacotherapy. 2013;33:1264–72.PubMedCrossRef Madigan T, Sieve RM, Graner KK, Banerjee R. The effect of age and weight on vancomycin serum trough concentrations in pediatric patients. Pharmacotherapy. 2013;33:1264–72.PubMedCrossRef
32.
Zurück zum Zitat Roumeliotis N, Pullenayegum E, Rochon P, Taddio A, Parshuram C. A modified Delphi to define drug dosing errors in pediatric critical care. BMC Pediatr. 2020;20:488.PubMedPubMedCentralCrossRef Roumeliotis N, Pullenayegum E, Rochon P, Taddio A, Parshuram C. A modified Delphi to define drug dosing errors in pediatric critical care. BMC Pediatr. 2020;20:488.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Schouwers S, Verstraete A, Stove V. Analytical evaluation of phenytoin, phenobarbital, valproic acid and vancomycin assays on the Abbott Architect (TM). Acta Clin Belg. 2010;65:211. Schouwers S, Verstraete A, Stove V. Analytical evaluation of phenytoin, phenobarbital, valproic acid and vancomycin assays on the Abbott Architect (TM). Acta Clin Belg. 2010;65:211.
34.
Zurück zum Zitat He N, Dong F, Liu W, Zhai S. A systematic review of vancomycin dosing in patients with hematologic malignancies or neutropenia. Infect Drug Resist. 2020;13:1807–21.PubMedPubMedCentralCrossRef He N, Dong F, Liu W, Zhai S. A systematic review of vancomycin dosing in patients with hematologic malignancies or neutropenia. Infect Drug Resist. 2020;13:1807–21.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Hong LT, Goolsby TA, Sherman DS, Mueller SW, Reynolds P, Cava L, et al. Continuous infusion vs. intermittent vancomycin in neurosurgical intensive care unit patients. J Crit Care. 2015;30(1153):e1-6. Hong LT, Goolsby TA, Sherman DS, Mueller SW, Reynolds P, Cava L, et al. Continuous infusion vs. intermittent vancomycin in neurosurgical intensive care unit patients. J Crit Care. 2015;30(1153):e1-6.
36.
Zurück zum Zitat Hanrahan T, Whitehouse T, Lipman J, Roberts JA. Vancomycin-associated nephrotoxicity: a meta-analysis of administration by continuous versus intermittent infusion. Int J Antimicrob Agents. 2015;46:249–53.PubMedCrossRef Hanrahan T, Whitehouse T, Lipman J, Roberts JA. Vancomycin-associated nephrotoxicity: a meta-analysis of administration by continuous versus intermittent infusion. Int J Antimicrob Agents. 2015;46:249–53.PubMedCrossRef
37.
Zurück zum Zitat Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:17–24.PubMedCrossRef Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:17–24.PubMedCrossRef
38.
Zurück zum Zitat Rainkie D, Ensom MH, Carr R. Pediatric assessment of vancomycin empiric dosing (PAVED): a retrospective review. Paediatr Drugs. 2015;17:245–53.PubMedCrossRef Rainkie D, Ensom MH, Carr R. Pediatric assessment of vancomycin empiric dosing (PAVED): a retrospective review. Paediatr Drugs. 2015;17:245–53.PubMedCrossRef
39.
Zurück zum Zitat Chang CN, Lo WT, Chan MC, Wang CC. A retrospective study to estimate serum vancomycin trough concentrations in pediatric patients with current recommended dosing regimen. J Med Sci. 2018;38:275–9.CrossRef Chang CN, Lo WT, Chan MC, Wang CC. A retrospective study to estimate serum vancomycin trough concentrations in pediatric patients with current recommended dosing regimen. J Med Sci. 2018;38:275–9.CrossRef
40.
Zurück zum Zitat Alves G, Chequer FMD, Sanches C. Effective vancomycin concentrations in children: a cross-sectional study. Einstein (Sao Paulo). 2019;17:eAO4396.CrossRef Alves G, Chequer FMD, Sanches C. Effective vancomycin concentrations in children: a cross-sectional study. Einstein (Sao Paulo). 2019;17:eAO4396.CrossRef
41.
Zurück zum Zitat Rajon K, Vaillancourt R, Varughese N, Villarreal G. Vancomycin use, dosing and serum trough concentrations in the pediatric population: a retrospective institutional review. Pharm Pract (Granada). 2017;15:887.CrossRef Rajon K, Vaillancourt R, Varughese N, Villarreal G. Vancomycin use, dosing and serum trough concentrations in the pediatric population: a retrospective institutional review. Pharm Pract (Granada). 2017;15:887.CrossRef
42.
Zurück zum Zitat Hirai K, Ihara S, Kinae A, Ikegaya K, Suzuki M, Hirano K, et al. Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance. Ther Drug Monit. 2016;38:393–7.PubMedCrossRef Hirai K, Ihara S, Kinae A, Ikegaya K, Suzuki M, Hirano K, et al. Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance. Ther Drug Monit. 2016;38:393–7.PubMedCrossRef
43.
Zurück zum Zitat Badran EF, Shamayleh A, Irshaid YM. Pharmacokinetics of vancomycin in neonates admitted to the neonatology unit at the Jordan University Hospital. Int J Clin Pharmacol Ther. 2011;49:252–7.PubMedCrossRef Badran EF, Shamayleh A, Irshaid YM. Pharmacokinetics of vancomycin in neonates admitted to the neonatology unit at the Jordan University Hospital. Int J Clin Pharmacol Ther. 2011;49:252–7.PubMedCrossRef
44.
Zurück zum Zitat Frymoyer A, Hersh AL, El-Komy MH, Gaskari S, Su F, Drover DR, Van Meurs K. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. Antimicrob Agents Chemother. 2014;58:6454–61.PubMedPubMedCentralCrossRef Frymoyer A, Hersh AL, El-Komy MH, Gaskari S, Su F, Drover DR, Van Meurs K. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. Antimicrob Agents Chemother. 2014;58:6454–61.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Frymoyer A, Stockmann C, Hersh AL, Goswami S, Keizer RJ. Individualized empiric vancomycin dosing in neonates using a model-based approach. J Pediatric Infect Dis Soc. 2019;8:97–104.PubMedCrossRef Frymoyer A, Stockmann C, Hersh AL, Goswami S, Keizer RJ. Individualized empiric vancomycin dosing in neonates using a model-based approach. J Pediatric Infect Dis Soc. 2019;8:97–104.PubMedCrossRef
46.
Zurück zum Zitat Reilly AM, Ding MX, Rower JE, Kiser TH. The effectiveness of a vancomycin dosing guideline in the neonatal intensive care unit for achieving goal therapeutic trough concentrations. J Clin Pharmacol. 2019;59:997–1005.PubMedCrossRef Reilly AM, Ding MX, Rower JE, Kiser TH. The effectiveness of a vancomycin dosing guideline in the neonatal intensive care unit for achieving goal therapeutic trough concentrations. J Clin Pharmacol. 2019;59:997–1005.PubMedCrossRef
47.
Zurück zum Zitat Swartling M, Gupta R, Dudas V, Guglielmo BJ. Short term impact of guidelines on vancomycin dosing and therapeutic drug monitoring. Int J Clin Pharm. 2012;34:282–5.PubMedCrossRef Swartling M, Gupta R, Dudas V, Guglielmo BJ. Short term impact of guidelines on vancomycin dosing and therapeutic drug monitoring. Int J Clin Pharm. 2012;34:282–5.PubMedCrossRef
48.
Zurück zum Zitat Traugott KA, Maxwell PR, Green K, Frei C, Lewis JS. Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders. Am J Health Syst Pharm. 2011;68:347–52.PubMedCrossRef Traugott KA, Maxwell PR, Green K, Frei C, Lewis JS. Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders. Am J Health Syst Pharm. 2011;68:347–52.PubMedCrossRef
49.
Zurück zum Zitat Seng JJB, Yong MHA, Peh ZX, Soong JL, Tan MH. Appropriateness of vancomycin therapeutic drug monitoring and its outcomes among non-dialysis patients in a tertiary hospital in Singapore. Int J Clin Pharm. 2018;40:977–81.PubMedCrossRef Seng JJB, Yong MHA, Peh ZX, Soong JL, Tan MH. Appropriateness of vancomycin therapeutic drug monitoring and its outcomes among non-dialysis patients in a tertiary hospital in Singapore. Int J Clin Pharm. 2018;40:977–81.PubMedCrossRef
50.
Zurück zum Zitat Suryadevara M, Steidl KE, Probst LA, Shaw J. Inappropriate vancomycin therapeutic drug monitoring in hospitalized pediatric patients increases pediatric trauma and hospital costs. J Pediatr Pharmacol Ther. 2012;17:159–65.PubMedPubMedCentral Suryadevara M, Steidl KE, Probst LA, Shaw J. Inappropriate vancomycin therapeutic drug monitoring in hospitalized pediatric patients increases pediatric trauma and hospital costs. J Pediatr Pharmacol Ther. 2012;17:159–65.PubMedPubMedCentral
51.
Zurück zum Zitat Colin PJ, Allegaert K, Thomson AH, Touw DJ, Dolton M, de Hoog M, et al. Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations. Clin Pharmacokinet. 2019;58:767–80.PubMedCrossRef Colin PJ, Allegaert K, Thomson AH, Touw DJ, Dolton M, de Hoog M, et al. Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations. Clin Pharmacokinet. 2019;58:767–80.PubMedCrossRef
52.
Zurück zum Zitat Newham R, Thomson AH, Semple Y, Dewar S, Steedman T, Bennie M. Barriers to the safe and effective use of intravenous gentamicin and vancomycin in Scottish hospitals, and strategies for quality improvement. Eur J Hosp Pharm. 2015;22:32–7.CrossRef Newham R, Thomson AH, Semple Y, Dewar S, Steedman T, Bennie M. Barriers to the safe and effective use of intravenous gentamicin and vancomycin in Scottish hospitals, and strategies for quality improvement. Eur J Hosp Pharm. 2015;22:32–7.CrossRef
53.
Zurück zum Zitat Chan JOS, Baysari MT, Carland JE, Sandaradura I, Moran M, Day RO. Barriers and facilitators of appropriate vancomycin use: prescribing context is key. Eur J Clin Pharmacol. 2018;74:1523–9.PubMedCrossRef Chan JOS, Baysari MT, Carland JE, Sandaradura I, Moran M, Day RO. Barriers and facilitators of appropriate vancomycin use: prescribing context is key. Eur J Clin Pharmacol. 2018;74:1523–9.PubMedCrossRef
54.
Zurück zum Zitat Van Dort BA, Baysari MT, Carland JE, Stocker SL, Braithwaite HE, Fernon AR, et al. Education to improve vancomycin use—the perspectives of educators and education recipients. Intern Med J. 2020;50:565–72.PubMedCrossRef Van Dort BA, Baysari MT, Carland JE, Stocker SL, Braithwaite HE, Fernon AR, et al. Education to improve vancomycin use—the perspectives of educators and education recipients. Intern Med J. 2020;50:565–72.PubMedCrossRef
55.
Zurück zum Zitat Phillips CJ, McKinnon RA, Woodman RJ, Gordon DL. Sustained improvement in vancomycin dosing and monitoring post-implementation of guidelines: results of a three-year follow-up after a multifaceted intervention in an Australian teaching hospital. J Infect Chemother. 2018;24:103–9.PubMedCrossRef Phillips CJ, McKinnon RA, Woodman RJ, Gordon DL. Sustained improvement in vancomycin dosing and monitoring post-implementation of guidelines: results of a three-year follow-up after a multifaceted intervention in an Australian teaching hospital. J Infect Chemother. 2018;24:103–9.PubMedCrossRef
56.
Zurück zum Zitat Minne L, Eslami S, Kuiper RA, Abu-Hanna A, Dongelmans DA. Five years of therapeutic drug monitoring in the intensive care did not change vancomycin prescription behaviour: perceived needs for decision support. Minerva Anestesiol. 2012;78:684–92.PubMed Minne L, Eslami S, Kuiper RA, Abu-Hanna A, Dongelmans DA. Five years of therapeutic drug monitoring in the intensive care did not change vancomycin prescription behaviour: perceived needs for decision support. Minerva Anestesiol. 2012;78:684–92.PubMed
57.
Zurück zum Zitat Pea F, Cojutti P, Dose L, Baraldo M. A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? Br J Clin Pharmacol. 2016;81:341–8.PubMedCrossRef Pea F, Cojutti P, Dose L, Baraldo M. A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? Br J Clin Pharmacol. 2016;81:341–8.PubMedCrossRef
58.
Zurück zum Zitat Girand HL. Continuous infusion vancomycin in pediatric patients: a critical review of the evidence. J Pediatr Pharmacol Ther. 2020;25:198–214.PubMedPubMedCentral Girand HL. Continuous infusion vancomycin in pediatric patients: a critical review of the evidence. J Pediatr Pharmacol Ther. 2020;25:198–214.PubMedPubMedCentral
59.
Zurück zum Zitat Gwee A, Cranswick N, Donath SM, Hunt R, Curtis N. Protocol for a randomised controlled trial of continuous infusions of vancomycin to improve the attainment of target vancomycin levels in young infants: the VANC trial. BMJ Open. 2018;8:e022603.PubMedPubMedCentralCrossRef Gwee A, Cranswick N, Donath SM, Hunt R, Curtis N. Protocol for a randomised controlled trial of continuous infusions of vancomycin to improve the attainment of target vancomycin levels in young infants: the VANC trial. BMJ Open. 2018;8:e022603.PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Berthaud R, Benaboud S, Hirt D, Genuini M, Oualha M, Castelle M, et al. Early Bayesian dose adjustment of vancomycin continuous infusion in children: a randomized controlled trial. Antimicrob Agents Chemother. 2019;63(12):e01102-e1119.PubMedCentralCrossRef Berthaud R, Benaboud S, Hirt D, Genuini M, Oualha M, Castelle M, et al. Early Bayesian dose adjustment of vancomycin continuous infusion in children: a randomized controlled trial. Antimicrob Agents Chemother. 2019;63(12):e01102-e1119.PubMedCentralCrossRef
61.
Zurück zum Zitat Allegaert K, Flint R, Smits A. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle. Expert Opin Drug Metab Toxicol. 2019;2019:1–15. Allegaert K, Flint R, Smits A. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle. Expert Opin Drug Metab Toxicol. 2019;2019:1–15.
62.
Zurück zum Zitat Stoessel AM, Hale CM, Seabury RW, Miller CD, Steele JM. The impact of AUC-based monitoring on pharmacist-directed vancomycin dose adjustments in complicated methicillin-resistant staphylococcus aureus infection. J Pharm Pract. 2019;32:442–6.PubMedCrossRef Stoessel AM, Hale CM, Seabury RW, Miller CD, Steele JM. The impact of AUC-based monitoring on pharmacist-directed vancomycin dose adjustments in complicated methicillin-resistant staphylococcus aureus infection. J Pharm Pract. 2019;32:442–6.PubMedCrossRef
63.
Zurück zum Zitat Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH. Vancomycin area under the curve and acute kidney injury: a meta-analysis. Clin Infect Dis. 2019;69:1881–7.PubMedPubMedCentralCrossRef Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH. Vancomycin area under the curve and acute kidney injury: a meta-analysis. Clin Infect Dis. 2019;69:1881–7.PubMedPubMedCentralCrossRef
64.
Zurück zum Zitat Finch NA, Zasowski EJ, Murray KP, Mynatt RP, Zhao JJ, Yost R, et al. A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrob Agents Chemother. 2017;61(12):e01293-e1317.PubMedPubMedCentralCrossRef Finch NA, Zasowski EJ, Murray KP, Mynatt RP, Zhao JJ, Yost R, et al. A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrob Agents Chemother. 2017;61(12):e01293-e1317.PubMedPubMedCentralCrossRef
65.
Zurück zum Zitat McNeil JC, Kaplan SL. Vancomycin therapeutic drug monitoring in children: new recommendations, similar challenges. J Pediatr Pharmacol Ther. 2020;25:472–5.PubMedPubMedCentral McNeil JC, Kaplan SL. Vancomycin therapeutic drug monitoring in children: new recommendations, similar challenges. J Pediatr Pharmacol Ther. 2020;25:472–5.PubMedPubMedCentral
66.
Zurück zum Zitat Carpenter GW, Myers HG, Sherer EA, Evans KA, O’Neal DP. Closed-loop intravenous drug administration using photoplethysmography. IEEE J Transl Eng Health Med. 2018;6:4300108.PubMedCrossRef Carpenter GW, Myers HG, Sherer EA, Evans KA, O’Neal DP. Closed-loop intravenous drug administration using photoplethysmography. IEEE J Transl Eng Health Med. 2018;6:4300108.PubMedCrossRef
Metadaten
Titel
Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life
verfasst von
Tatjana Van Der Heggen
Franky M. Buyle
Barbara Claus
Annemie Somers
Petra Schelstraete
Peter De Paepe
Sophie Vanhaesebrouck
Pieter A. J. G. De Cock
Publikationsdatum
28.04.2021
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 5/2021
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-021-01266-7

Weitere Artikel der Ausgabe 5/2021

International Journal of Clinical Pharmacy 5/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.